Cytophage Technologies Closes First Tranche of Private Placement, Raises $1.002 Million
WINNIPEG, November 13, 2025 — Leads & Copy — Cytophage Technologies Ltd. (TSXV: CYTO, FSE: 70G) has closed the first tranche of its non-brokered private placement, raising $1.002 million through the issuance of 5,010,000 units to investors.
The company announced the closing of the first tranche of its previously announced non-brokered private placement. The initial details of the offering were disclosed in a press release dated October 17, 2025. Cytophage intends to close a secondary tranche around November 17, 2025.
According to an earlier press release, Cytophage may increase the offering by up to 3,000,000 units, potentially raising an additional $600,000, to meet investor demand.
Each unit comprises one common share of the company and one-half of a common share purchase warrant. A whole warrant allows the holder to buy one additional share at C$0.40 per share for 24 months from the issue date. Cytophage can expedite the warrants’ expiration if its common shares’ volume-weighted average trading price on the TSX Venture Exchange reaches or surpasses $0.60 for 10 consecutive trading days.
If Cytophage exercises this acceleration right, it will notify all warrant holders. The company also agreed to pay finder’s fees of $34,440 in cash and issue 172,200 broker warrants with the same terms as the offering’s warrants to qualified, unrelated parties, pending exchange approval.
All securities issued during the first tranche closing are subject to a four-month hold period, which will expire on March 11, 2026, in accordance with the exchange’s regulations and Canadian securities laws.
Directors and senior officers collectively purchased 150,000 units, accounting for about 3.0% of the first-tranche closing, totaling C$30,000 in gross proceeds. The purchase of units by these insiders is a related party transaction under Multilateral Instrument 61-101. The company is relying on exemptions from the valuation and minority shareholder approval requirements outlined in sections 5.5(b) and 5.7(1)(a) of MI 61-101, given the company’s non-listing on a specified market and the insiders’ participation not exceeding 25% of the company’s market capitalization.
Cytophage will use the offering’s net proceeds to further its phage technology in human health, animal health, and food security, along with general corporate needs. The offering’s closing is contingent upon receiving all necessary regulatory approvals from the TSX Venture Exchange.
The offered securities have not been registered under the U.S. Securities Act of 1933 and cannot be sold in the United States without registration or an applicable exemption. This announcement is not an offer to sell or a solicitation to buy securities in any jurisdiction where such an offer would be unlawful.
Cytophage Technologies (TSXV:CYTO / FSE: 70G) focuses on bacteriophage research, development, and commercialization. Bacteriophages are viruses that infect and kill bacteria, overcoming cellular defenses as nature’s antibiotics.
The company is enhancing these natural bacteria killers to offer safe and toxin-free solutions for large markets, initially targeting animal health for near-term revenue. As a leading bacteriophage manufacturer in Canada, Cytophage addresses antibiotic resistance, which the WHO predicts will be the leading cause of human mortality by 2050.
Preventative antibiotic use in animal production has been banned or limited in many countries, including the 27 EU countries, the US, Canada, Brazil, Bangladesh, India, and Mexico. Consumers worldwide increasingly demand organic and antibiotic-free products. Cytophage employs a de-risked and patented technology to create innovative and cost-competitive products that leverage bacteriophages to combat bacterial infections in human health, animal health, and food security.
For additional information, contact Julius Kalcevich, Chief Financial Officer at julius.kalcevich@cytophage.com or 647 705 5544.
Cytophage Investor Alerts: https://cytophage.com/subscribe/
Source: Cytophage Technologies Ltd.
Share this story:
